# N4 Pharma raises £2 million through placing

- Link: https://www.directorstalkinterviews.com/n4-pharma-raises-2-million-through-placing/412946445
- Published: 2020-12-09T08:19:32+00:00
- Author: Amilia Stone

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has announced that
it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary
shares of 0.4p each in the Company at an issue price of 8p per Placing Share.  The
Placing, which was significantly oversubscribed, was undertaken by SP Angel Corporate
Finance LLP.

The net proceeds of the Placing will be used for:

·    the extension of the formulation and current stability work covering DNA and
mRNA formulations;

·    research on and evaluation of an additional asset to add to the Company portfolio;

·    business development driven by study results pending over next six months; 
and

·    ongoing working capital.

**Application for Admission**

The Placing has been conducted utilising the Company’s existing share authorities.
Application has been made for the Placing Shares to be admitted to trading on AIM(“
Admission”) and it is expected that Admission will take place and that trading will
commence on AIM at 8.00 a.m. on or around 14 December 2020.  Once issued, the new
Ordinary Shares will rank _pari passu_ with the Company’s existing ordinary shares.

**Total Voting Rights**

Following Admission, the enlarged issued share capital of the Company will comprise
181,080,349 Ordinary Shares of 0.4 pence each.  The Company does not hold any ordinary
shares in treasury.  Consequently, 181,080,349 is the figure which may be used by
shareholders as the denominator for the calculation by which they will determine
if they are required to notify their interest in, or a change to their interest 
in, the Company under the FCA’s Disclosure and Transparency Rules.

> **Nigel Theobald, Chief Executive of N4 Pharma, commented:** “We are delighted
> with the positive response to our recent formulation work.  With vaccines and 
> their delivery very much in the public consciousness we continue to grow our data
> package to present Nuvec® as a viable delivery technology solution to improve 
> the delivery, storage and transportation of multiple existing and new vaccines.
> “Whilst we are well funded for all existing work streams these additional funds
> will enable us to plan for follow on studies and more product focussed experiments
> as we move towards collaborations.”  

Share on:
